首页 文献索引 SCI期刊 AI助手
期刊目录筛选

期刊名:Oncogene

缩写:ONCOGENE

ISSN:0950-9232

e-ISSN:1476-5594

IF/分区:7.3/Q1

文章目录 更多期刊信息

共收录本刊相关文章索引9654
Clinical Trial Case Reports Meta-Analysis RCT Review Systematic Review
Classical Article Case Reports Clinical Study Clinical Trial Clinical Trial Protocol Comment Comparative Study Editorial Guideline Letter Meta-Analysis Multicenter Study Observational Study Randomized Controlled Trial Review Systematic Review
Jun-Kyum Kim,Min Gi Park,Seok Won Ham et al. Jun-Kyum Kim et al.
Malignant cancers exhibit distinct lipid metabolic features that support tumor initiation and progression. Glioblastoma (GBM) is an aggressive brain tumor driven by GBM stem cells (GSCs), which are responsible for tumor development and ther...
Xi Wang,Guangyan Li,Jiaming Wu et al. Xi Wang et al.
Immune checkpoint blockade (ICB) targeting PD-1/PD-L1 improves outcomes across multiple malignancies, yet resistance to immune checkpoint blockade remains common. Here, we identify HILPDA as a tumor-intrinsic regulator of immune evasion in ...
Hongji Hu,Xiangpeng Zhan,Yunqiang Xiong et al. Hongji Hu et al.
The paper ( https://doi.org/10.1038/s41388-025-03410-3 ) was retracted due to the use of a contaminated cell line; after communication with the original journal's editors, we have obtained permission to replace the cell line and resubmit th...
Lin Yao,Heyang Gao,Zuopeng Su et al. Lin Yao et al.
Glioblastoma multiforme (GBM) is a highly aggressive primary brain tumor that represents a significant therapeutic challenge because of its immunosuppressive tumor microenvironment (TME). GBM employs multiple sophisticated mechanisms for im...
Chia-Hui Chen,Ryan Brown,Donald J Vander Griend et al. Chia-Hui Chen et al.
The introduction of next-generation androgen receptor signaling inhibitors (ARSIs) like enzalutamide (ENZ), has improved the clinical management of castration-resistant prostate cancer (CRPC). However, acquired resistance to these therapies...
Jessamy Adams,Caterina M Suelzu,Gabriele Strusi et al. Jessamy Adams et al.
Alterations in metabolism are recognised as a hallmark of cancer, allowing for rapid proliferation in an environment often hypoxic and short of nutrients. Cells within the tumour microenvironment (TME) often undergo metabolic alterations to...
Zijian Kuang,Qiliang Su,Wenken Liang et al. Zijian Kuang et al.
Cancer cells exhibit abnormally altered proteome to satisfy the metabolic demands that arise from heightened proliferation. Trypsin-like serine proteases are a class of proteolytic enzymes whose expression is often dysregulated in cancer. S...
Siyu Zhang,Wenyue Chen,Ji Yang et al. Siyu Zhang et al.
Ferroptosis is a form of iron-dependent programmed cell death (PCD) that, once activated, inhibits tumor progression. However, the specific mechanisms influencing ferroptosis in nasopharyngeal carcinoma (NPC) are limited and warrant further...
Guanli Wang,Xuejie Gao,Hui Zhang et al. Guanli Wang et al.
Proteasome inhibitor (PI) resistance remains a major barrier in the treatment of multiple myeloma (MM), underscoring the urgent need to elucidate underlying mechanisms and identify actionable therapeutic targets. Here, we uncover METTL16 as...
Koushik Guchhait,Hyeon-Seung Yoon,Hyun-Su An et al. Koushik Guchhait et al.
Metastasis is the primary cause of mortality in advanced prostate cancer, and the emergence of resistance to androgen receptor (AR)-targeted therapies highlights the urgent need for alternative therapeutic strategies. Metabolic reprogrammin...